BUSINESS● LOWAug 14 · Aug 14, 2026, 5:08 PM
Outlook Therapeutics targets more than $500M peak annual LYTENAVA sales by 2030 as it forecasts $50M-$75M first-year net revenue
Seeking Alpha Tech
Outlook Therapeutics is projecting significant peak annual sales for its product LYTENAVA by 2030 and forecasting first-year net revenue. This provides insight into the company's financial outlook and product performance expectations.
GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text.
More in Business
BUSINESSnowMunicipal Securities Underwriters Pay a Total of $325,000 in FinesSECBUSINESSnowSEC CHAIRMAN ARTHUR LEVITT, IOWA OFFICIALS TO HOLD INVESTORS’ TOWN MEETING IN DES MOINESSECBUSINESS43m agoGold market consolidating rather than entering bear market, Metals Focus analyst saysSeeking Alpha TechBUSINESS45m agoCollegium resolves Nucynta patent dispute with GrünenthalSeeking Alpha Tech